Through its New Therapeutic Uses program, NCATS aims to improve the process of developing new treatments and cures for disease by finding new uses for existing therapies that already have cleared several key steps along the development path. Many existing or partially developed therapeutic candidates can be repurposed for use in new disease indications. Bringing together the best assets from pharmaceutical companies with the best new ideas from academic researchers could produce new treatments much more quickly than starting from scratch. Read the latest news about these partnerships below.
In collaboration with AstraZeneca and Janssen Research & Development, LLC, NCATS is seeking applications to explore new treatments for patients using existing experimental drugs or biologics. Through its NIH-Industry Partnerships initiative, NCATS will support public-private partnerships by making a selection of industry assets available to test ideas for new therapeutic uses.
NCATS announces the Bench-to-Clinic Repurposing initiative and related funding opportunity. The goal is to support investigators to repurpose — or identify new uses for — existing experimental drugs or biologics, as well as Food and Drug Administration-approved therapies already on the market.
NCATS announces nearly $3 million to fund four drug repurposing projects aimed at finding therapies for type 2 diabetes, glioblastoma, acute myeloid leukemia and Chagas disease.
NCATS announces that scientists at Yale University have found that a compound originally developed as a cancer therapy could potentially be used to treat Alzheimer's disease. The team has begun testing the compound's effectiveness in humans.
NCATS announces the next round of New Therapeutic Uses funding opportunities to repurpose drug candidates from industry. For the first time, assets to treat pediatric indications will be available.
NCATS releases video and audio clips of New Therapeutic Uses-funded investigators discussing the program and their research.
NIH, including NCATS, launches the Discovering New Therapeutic Uses for Existing Molecules (New Therapeutic Uses) program at the National Press Club in Washington, D.C.